Cosmo Bio Co

Cosmo Bio Co EBITDA per Share

The EBITDA per Share of Cosmo Bio Co (3386.T) as of Oct 26, 2026 is 60.33 JPY. In the previous year, EBITDA per Share was 55.32 JPY — a change of 9.05% (higher).

EBITDA per Share

60.33JPY

YoY

9.05%

Last updated:

EBITDA per Share of Cosmo Bio Co is 2025 60.33 JPY. EBITDA per Share of Cosmo Bio Co was 2024 55.32 JPY. It decreases by 9.05% higher compared to the previous year.

The Cosmo Bio Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
55.50 JPY
Jan 1, 2019
68.49 JPY
Jan 1, 2020
126.86 JPY
Jan 1, 2021
180.94 JPY
Jan 1, 2022
140.37 JPY
Jan 1, 2023
88.94 JPY
Jan 1, 2024
55.32 JPY
Jan 1, 2025
60.33 JPY
The Cosmo Bio Co EBITDA per Share history
YEAREBITDA per ShareYoY
60.33JPY+9.05%
55.32JPY-37.80%
88.94JPY-36.64%
140.37JPY-22.42%
180.94JPY+42.64%
126.86JPY+85.22%
68.49JPY+23.40%
55.50JPY+69.59%
32.73JPY-57.28%
76.61JPY+117.91%
35.16JPY+23.31%
28.51JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cosmo Bio Co Stock analysis

What does Cosmo Bio Co do? Cosmo Bio Co., Ltd. generates revenue through the export, import, and sale of bio-research reagents, instruments, and software, as well as clinical diagnostics. The company imports research reagents primarily from the United States and Europe, which are utilized in life science research. In the equipment segment, Cosmo Bio handles specialized life science research equipment sourced from domestic and overseas suppliers, targeting domestic market sales. The equipment includes ultrasonic cell disruption devices, bioimaging systems, and research consumables. Clinical test drugs are sold mainly to hospitals and testing centers. The company's research reagents business focuses on importing products from the United States and Europe, which are prioritized for life science research applications. Equipment sales target domestic customers seeking specialized life science research tools, including ultrasonic cell disruption equipment and bioimaging-related devices. Clinical diagnostics products are distributed to hospitals and testing centers for medical testing purposes. Cosmo Bio's revenue streams are divided into three main segments: bio-research reagents, life science equipment, and clinical diagnostics. The reagents segment relies on imports from the United States and Europe, while the equipment segment features products like ultrasonic cell disruption equipment and bioimaging systems. Clinical diagnostics products are sold to hospitals and testing centers as test drugs for medical use. Cosmo Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cosmo Bio Co stock

EBITDA per Share of Cosmo Bio Co is 60.33 JPY in 2025.

EBITDA per Share of Cosmo Bio Co changed from 55.32 JPY to 60.33 JPY, representing a 9.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Cosmo Bio Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cosmo Bio Co

All Key Metrics — Cosmo Bio Co